Sigachi Industries Ltd
NSE:SIGACHI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sigachi Industries Ltd
NSE:SIGACHI
|
IN |
|
Hanshin Diesel Works Ltd
TSE:6018
|
JP |
|
Shaw Communications Inc
TSX:SJR.B
|
CA |
|
Livero Inc
TSE:9245
|
JP |
|
H
|
Huaan Securities Co Ltd
SSE:600909
|
CN |
|
A
|
Arax Holdings Corp.
OTC:ARAT
|
US |
|
T
|
Teikoku Electric Mfg. Co Ltd
TSE:6333
|
JP |
|
Y
|
Yunhong Guixin Group Holdings Ltd
HKEX:8349
|
CN |
|
Rocky Mountain Chocolate Factory Inc (Delaware)
NASDAQ:RMCF
|
US |
|
S
|
Shanghai Yct Electronics Group Co Ltd
SZSE:301099
|
CN |
|
Goodway Machine Corp
TWSE:1583
|
TW |
|
Solaris Oilfield Infrastructure Inc
NYSE:SOI
|
US |
|
S
|
Safkar Ege Sogutmacilik Klima Soguk Hava Tesisleri Ihracat Ithalat Sanayi Ve Ticaret AS
IST:SAFKR.E
|
TR |
|
S
|
Shikun & Binui Ltd
TASE:SKBN
|
IL |
|
A
|
Arena Group Holdings Inc
AMEX:AREN
|
US |
|
C
|
China Oceanwide Holdings Ltd
HKEX:715
|
HK |
|
Liberty Media Corp
NASDAQ:FWONA
|
US |
|
Hung Hing Printing Group Ltd
HKEX:450
|
HK |
|
Grovy India Ltd
BSE:539522
|
IN |
Sigachi Industries Ltd
Sigachi Industries Ltd. engages in the manufacture and sale of microcrystalline cellulose. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-11-15. The firm is engaged in manufacturing cellulose-based excipients for finished dosages in the pharmaceutical industry. The Company’s products include EXCiPACT GMP, SGMP, HACCP and EDQM CEP. The firm's pre-formulated excipients include BARETab PH, BARETab ODT and BARETab Nutra.The Company offers Anti-ulcers (Gastrointestinal) Products and their Intermediates. The firm serves pharmaceutical, food and nutraceuticals, cosmetic and chemical industries.
Sigachi Industries Ltd. engages in the manufacture and sale of microcrystalline cellulose. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2021-11-15. The firm is engaged in manufacturing cellulose-based excipients for finished dosages in the pharmaceutical industry. The Company’s products include EXCiPACT GMP, SGMP, HACCP and EDQM CEP. The firm's pre-formulated excipients include BARETab PH, BARETab ODT and BARETab Nutra.The Company offers Anti-ulcers (Gastrointestinal) Products and their Intermediates. The firm serves pharmaceutical, food and nutraceuticals, cosmetic and chemical industries.
Quarterly Performance: Sigachi reported Q3 operating income of INR 117.2 crores and an EBITDA margin of 4.6%, with a net loss of INR 0.02 crores.
Margin Pressure: EBITDA margin dropped sharply due to the ongoing impact of the Hyderabad plant fire, higher overheads, raw material costs, and temporary custom duty charges.
Capacity Expansion: The 12,000 metric ton MCC Dahej expansion and 1,800 ton CCS facility are on track for commissioning in Q3 FY '27, aiming to raise total capacity to 30,000 metric tons per annum.
Recovery Outlook: Management expects gradual margin and earnings normalization starting from Q4, with full recovery and double-digit EBITDA margins anticipated from FY '28 onwards.
Insurance Proceeds: The company expects to receive around INR 70 crores in insurance claims related to the Hyderabad incident, with an initial ad hoc payment likely before March 31.
No Demand Weakness: Management repeatedly emphasized stable demand and no pricing pressure in core MCC and API products—production constraints, not demand, are behind lower sales.
Balance Sheet: There is no long-term debt, only working capital borrowings; future capex may be funded by equity or debt as needed.
